GMAB vs ROIV
Genmab A/S and Roivant Sciences Ltd., both Healthcare
Genmab A/S is the larger company at $33B against $28B. GMAB keeps 29 cents of operating profit from each dollar of sales against -1358 for ROIV, and ROIV grew sales faster over the last year, +102% against +19%. Over the past year ROIV returned +83% against +75% for GMAB.
| Figure | GMAB | Both figures drawn to one scale | ROIV |
|---|---|---|---|
| Last close | $50.98 | $38.73 | |
| Market cap | $33B | $28B | |
| Trailing P/Eshare price over earnings per share | 33.2 | n/a | |
| Revenue growthlast twelve months on the year before | +19% | +102% | |
| Operating margin | 29% | minus 1358% | |
| Net margin | 26% | minus 838% | |
| Free cash flow yield | 3.5% | n/a | |
| Net cashcash minus all debt | $3.6B net debt | n/a | |
| Insiders, 12 monthsopen-market Form 4 trades | n/a | sold $895M net | |
| 1-year return | +75% | +83% | |
| 5-year return | +9.6% | +388% |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.
Genmab A/S
Revenue of $2.1B in the quarter to Dec 31, 2025, net income $432M.
Roivant Sciences Ltd.
Revenue of $35M in the quarter to Sep 30, 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.